Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 14/20 | 1.00 |
| ▸ | CNR1 | P21554 | 14/20 | 0.78 |
| ▸ | GPR55 | Q9Y2T6 | 4/20 | 0.53 |
| ▸ | GPR18 | Q14330 | 3/20 | 0.53 |
| ▸ | STS | P08842 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385309 | 1.00 | CNR2 (1.00) | CNR2CNR1GPR55GPR18STS | |
| SCHEMBL31629276 | 1.00 | CNR2 (1.00) | CNR2CNR1GPR55GPR18STS | |
| SCHEMBL17414493 | 1.00 | CNR2 (1.00) | CNR2CNR1GPR55GPR18STS | |
| SCHEMBL15994871 | 0.91 | CNR2 (0.84) | CNR2CNR1GPR55GPR18MAPT | |
| SCHEMBL15994870 | 0.88 | CNR2 (0.78) | CNR2CNR1GPR55GPR18STS | |
| SCHEMBL29385133 | 0.88 | CNR2 (1.00) | CNR2CNR1GPR55GPR18 | |
| SCHEMBL29929142 | 0.88 | CNR2 (1.00) | CNR2CNR1GPR55GPR18 | |
| SCHEMBL3298491 | 0.88 | CNR2 (1.00) | CNR2CNR1GPR55GPR18 | |
| SCHEMBL5550044 | 0.87 | CNR2 (0.82) | CNR2CNR1GPR55GPR18 | |
| SCHEMBL15995383 | 0.86 | CNR2 (0.75) | CNR2CNR1GPR55GPR18MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190314379-A1 | METHODS OF USING CANNABINOID CB2 RECEPTOR AGONIST COMPOSITIONS TO SUPPRESS AND PREVENT OPIOID TOLERANCE AND WITHDRAWAL IN A SUBJECT | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-10-17 | — | — | US | claimed |
| US-20190314379-A1 | METHODS OF USING CANNABINOID CB2 RECEPTOR AGONIST COMPOSITIONS TO SUPPRESS AND PREVENT OPIOID TOLERANCE AND WITHDRAWAL IN A SUBJECT | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
| US-20190314379-A1 | METHODS OF USING CANNABINOID CB2 RECEPTOR AGONIST COMPOSITIONS TO SUPPRESS AND PREVENT OPIOID TOLERANCE AND WITHDRAWAL IN A SUBJECT | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2019-10-17 | — | — | US | disclosed |
| US-7741365-B2 | Peripheral cannabinoid receptor (CB2) selective ligands | UNIVERSITY OF CONNECTICUT (US) | 2010-06-22 | — | — | US | disclosed |
| EP-1223808-B1 | PERIPHERAL CANNABINOID RECEPTOR (CB2) SELECTIVE LIGANDS | UNIV CONNECTICUT (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060189610-A1 | Peripheral cannabinoid receptor (CB2) selective ligands | UNIVERSITY OF CONNECTICUT | 2006-08-24 | — | — | US | disclosed |
| US-6995187-B1 | Peripheral cannabinoid receptor (CB2) selective ligands | UNIVERSITY OF CONNECTICUT (US) | 2006-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060189610-A1 | Peripheral cannabinoid receptor (CB2) selective ligands | CNR2, CNR1, GPR18 | CNR2 1/4885CNR1 2/4885GPR55 12/4885 |
| US-20190314379-A1 | METHODS OF USING CANNABINOID CB2 RECEPTOR AGONIST COMPOSITIONS TO SUPPRESS AND PREVENT OPIOID TOLERANCE AND WITHDRAWAL IN A SUBJECT | CNR2, CNR1, OPRK1 | CNR2 1/4885CNR1 2/4885GPR55 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.